BURLINGTON  Mass and OXFORD  UK  February 5  2018 – Blue Earth Diagnostics  a molecular imaging diagnostics company  today announced the upcoming presentation of initial results from the FALCON clinical trial (NCT02578940) of fluciclovine (18F) PET/CT  evaluating its impact on patient management in biochemically recurrent prostate cancer patients scheduled for salvage treatment with curative intent